Samarth Kulkarni, PhD, CEO of CRISPR Therapeutics, joins the show to chronical his journey to CRISPR Therapeutics and to break down the ins-and-outs of the technology. He begins by sharing the evolution of CRISPR as a “molecular scissors barcode” and it’s first viable indication; how he “bets” the technology will have a major footprint in the cancer, diabetes, and cardiovascular disease treatment landscapes; shares strategies for shortening the time to market for some of the products; explains how AI is used in his line of work; and a variety of other topics.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
